Summary by Moomoo AI
Eli Lilly and Co reported a significant increase in financial performance for the three and six months ended June 30, 2024. The company's revenue saw a substantial rise, with a 36% increase for the quarter, up from $11.3 billion in 2023 to $8.3 billion in 2024. Similarly, for the six-month period, revenue grew by 31%, from $20.1 billion in 2023 to $15.3 billion in 2024. Net income followed a similar trend, surging by 68% for both the quarter and six-month periods, reaching $3.0 billion and $5.2 billion respectively. Diluted earnings per share also saw a significant jump of 68% for the quarter, rising from $1.95 to $3.28, and a 67% increase for the six-month period, from $3.44 to $5.76. The growth in revenue and earnings was primarily attributed to increased sales of Mounjaro, Zepbound, and Verzenio, despite...Show More
